SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is a top trending stock following its latest earnings report, which, despite beating estimates, sparked a significant market downturn due to cautious forward guidance and concerns over slowing sales in China and the impact of tariffs. Community discussions highlight strong disappointment with management's conference call performance, yet many investors are actively debating if this sharp decline represents a compelling long-term buying opportunity.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst significant price declines, driven by broader crypto market weakness and anticipation of the Bank of Japan's interest rate decision. Community sentiment is polarized, with many expressing frustration over persistent drops, while strong proponents emphasize institutional accumulation and buying the dip, confident in its long-term utility for global financial infrastructure.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending after reports confirmed a binding agreement for a US joint venture involving TikTok's operations, with Oracle joining as a key investor and cloud provider. This news is fueling bullish sentiment, as many investors believe it significantly validates Oracle's cloud infrastructure and AI strategy, potentially outweighing recent debt concerns. Conversely, some in the community remain cautious, continuing to highlight the company's substantial debt load and questioning the long-term financial upside of the deal.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is a focal point following a Federal Reserve rate cut and upcoming Treasury bill purchases, which some in the community expect to fuel a rally in long bonds. Yet, considerable skepticism persists, with many observing that long-term yields are resisting downward pressure due to ongoing inflation concerns, questions about recent economic data's accuracy, and broader implications from central bank policy shifts including a potential new Fed chair. This creates a volatile environment as investors weigh easing efforts against market fundamentals.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending with significant momentum, primarily driven by high anticipation for an imminent NASA Lunar Terrain Vehicle (LTV) contract award, coupled with recent bullish analyst coverage and strong trading volume. The community is actively discussing LUNR's strategic advantage in lunar infrastructure, the potential for a substantial short squeeze, and broader market optimism for the space sector following an executive order on American space superiority.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending amidst intense community debate, as a broader crypto market downturn fuels discussion over persistent price suppression and perceived market manipulation. Despite ongoing developments like new council members and enterprise integrations for real-world assets, investors are sharply divided between accumulating at current levels and anticipating further declines. The conversation revolves around HBAR's long-term utility in a compliance-first environment versus short-term market volatility and macroeconomic pressures.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending amidst significant trading volume and positive clinical data for its CAN-2409 immunotherapy across prostate, pancreatic, and lung cancers. The community is actively discussing the stock's perceived undervaluation, anticipating a substantial short squeeze fueled by high short interest. Many speculate about an imminent partnership or acquisition, believing its oncology pipeline holds multi-billion dollar market potential.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending due to recent analyst upgrades, including a new "Buy" rating and an $18 price target from Benchmark, fueling investor optimism. The community is highly anticipating strong Black Friday sales results and discussing the company's long-term growth potential within the expanding African e-commerce market, despite acknowledging past volatility.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries (GTBIF) is a major trending topic as the cannabis sector anticipates pivotal regulatory shifts, including potential federal rescheduling to Schedule III and recent actions clarifying the hemp market. Despite some initial market volatility seen as a 'sell the news' reaction, the community largely views these developments as monumental catalysts, highlighting GTBIF's strong financials and market leadership as key factors for substantial long-term growth driven by tax relief and future institutional investment.

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Athira Pharma Inc

Athira Pharma is trending following its announcement of exclusively licensing a late-stage breast cancer drug program and securing substantial financing to advance its development. This news has ignited significant trading volume, with many anticipating a potential short squeeze fueled by the low float, while others express caution regarding potential dilution and the stock's historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company secured the exclusive global licence from Ohio-based Sermonix Pharmaceuticals.</li><li>Athira announced an upfront private placement financing of $90 million, which includes warrants that could provide an additional $146 million if exercised.</li><li>The stock is on track to open at its highest levels in over a year.</li></ul>Shares of Athira Pharma, Inc. (ATHA) jumped over 60% in premarket trading on Thursday after the company secured exclusive rights to a Phase 3 breast cancer drug and announced a $236 million financing package to support its development.<a href="https://stocktwits.com/symbol/ATHA">ATHA stock</a> is on track to open at its highest levels since November 2024.<h2 class="st-heading-2">Licensing Deal With Sermonix</h2>The clinical-stage biopharmaceutical company acquired an exclusive global license (excluding Asia and select Middle East countries) from Sermonix Pharmaceuticals to develop and commercialize lasofoxifene, a selective estrogen receptor modulator (SERM) for the potential treatment of metastatic breast cancer. The asset is currently in the Phase 3 ELAINE-3 trial, with topline data expected in mid-2027.As part of the agreement, Athira will issue Sermonix a pre-funded warrant to purchase roughly 5.5 million shares and is also obligated to make milestone payments up to $100 million, along with royalties on net sales ranging from sub-single to low-single digits, depending on territory and performance.<h2 class="st-heading-2">$236M Financing Program</h2>To support the program, Athira announced an upfront private placement financing of $90 million, co-led by Commodore Capital, Perceptive Advisors, and TCGX, with participation from multiple investors, including Blackstone Multi-Asset Investing and NEA. The financing includes warrants that could provide an additional $146 million if exercised.The proceeds are expected to fund lasofoxifene development through key clinical and regulatory milestones, supporting operations into 2028.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:913/91;" src="https://news.stocktwits-cdn.com/Athira_png_2d5f87b3d0.webp" alt="Athira.png" width="913" height="91"><figcaption>ATHA's Sentiment Meter and Message Volumes in Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>One user sees a strong setup with the potential for the stock to climb to $20. It is currently trading close to $7.<stembedurl>https://stocktwits.com/Catchmeifucan82/message/639539041</stembedurl>Another user expects further gains post-dilution.<stembedurl>https://stocktwits.com/GuyFawkes_EOD/message/639541743</stembedurl>Athira had completed a 10-for-1 reverse stock split of its common stock, which became effective on September 17.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/spir-stock-jumped-pentagon-151b-shield-contract/cLego7kREAp">A $151B Pentagon SHIELD Contract Has Put This Smallcap Satellite Stock Back On Traders’ Radar</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally?

Athira Pharma secured exclusive rights to a Phase 3 breast cancer drug and announced a $236 million financing package to support its development.

Equity

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Stocktwits Polls

Traders are celebrating significant profits and noting its frequent appearance on momentum scanners as a top performer today.

Intense debate surrounds the high risks of holding overnight, with warnings of dilution, pump-and-dump tactics, and manipulation in biotech small caps.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.58	--	--	N/A
Q3 '25	-$1.06	-$1.68	-58.49%	MISSED
Q2 '25	-$0.15	-$1.80	-1073.92%	MISSED
Q1 '25	-$0.24	-$0.23	4.17%	BEAT
Q4 '24	-$0.38	-$0.38	--	EXPECTED

ATHA
Athira Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ATHA News

ATHAAthira Pharma Inc